Gotrade News - Cathie Wood's ARK Investment Management bought Tempus AI, GeneDx, and CoreWeave this week. The firm also trimmed AMD and Rocket Lab, signaling a fresh rotation inside its flagship innovation funds.
According to Seeking Alpha, the moves landed in ARK's weekly trade recap for the period ending Friday. Per the report, the buys lean into clinical AI and AI infrastructure while the sells lock in gains on crowded names.
Key Takeaways:
- ARK Invest bought TEM, WGS, and CRWV in its latest weekly recap.
- The fund trimmed AMD and Rocket Lab after sharp recent rallies.
- The rotation points to clinical AI, genomics, and AI infra as ARK's next leg.
What ARK Bought This Week
ARK added Tempus AI, a clinical AI and genomics data platform, across multiple ETFs this week. As reported by Seeking Alpha, the position was scaled up alongside two other healthcare and AI infra names.
GeneDx, which trades under the WGS ticker, was the second buy and represents a whole-genome sequencing play. According to Motley Fool, GeneDx has positioned itself as a bargain entry into the genomics theme after recent share-price pressure.
CoreWeave rounded out the buy list and reinforces ARK's exposure to AI cloud GPU infrastructure. Per Seeking Alpha, the firm has been adding to CoreWeave (CRWV) on relative weakness in the AI infra cohort.
Wood frames these additions as undervalued exposure to the next leg of the AI build-out. According to Motley Fool, the buys share a common thread of clinical and infrastructure depth rather than headline AI consumer names.
What ARK Sold
ARK trimmed Advanced Micro Devices, one of the most-watched AI semiconductor names in 2026. Per Seeking Alpha, the sale follows a strong run for Advanced Micro Devices (AMD) tied to data center GPU demand.
Rocket Lab was the other notable trim in this week's recap. As reported by Seeking Alpha, the sale comes after RKLB's aerospace-driven rally pushed the position into trim territory across ARK funds.
The pattern suggests profit-taking on names that have already delivered outsized returns. According to Motley Fool, ARK has historically rotated out of consensus winners and into earlier-stage AI-adjacent stories when valuations stretch.
The Wider Read for Retail Investors
The buy list signals where ARK sees the AI thesis spreading next. Per Seeking Alpha, clinical AI via Tempus AI and genomics via GeneDx point to healthcare as the next ARK-favored adjacency.
CoreWeave underscores that AI infrastructure remains core to the thesis even as semis like AMD are trimmed. According to Motley Fool, the move suggests ARK prefers AI infra exposure through cloud and compute over crowded chip trades.
For global retail investors, the takeaway is a contrast between consensus AI semis and ARK's emerging picks. As reported by Seeking Alpha, the weekly recap can preview where active managers see the next unlock.
We suggest investors treat ARK's moves as one data point, not a buy signal on their own. Position sizing and fundamentals still matter more than tracking any single fund's weekly rotation.
Sources:
